Strategic characterization of anti-drug antibody responses for the assessment of clinical relevance and impact.

All therapeutic proteins have the potential to induce anti-drug antibodies (ADA). Clinically relevant ADA can impact efficacy and/or safety of a biological therapeutic. Immunogenicity assessment strategy evaluates binding and neutralizing ADA, and the need for additional characterization (e.g., epitope, titer and so on) is determined using a risk-based approach. The choice of characterization assays depends on the type, application and immunogenicity of the therapeutic. ADA characterization can impact the interpretation of the risk profile of a given therapeutic, and offers insight into opportunities for risk mitigation and management. This article describes common ADA characterization methods. Strategic assessment and characterization of clinically relevant ADA are discussed, in order to support clinical options for safe and effective patient care and disease management.

[1]  V. Jawa,et al.  Impact of Anti-Drug Antibodies in Preclinical Pharmacokinetic Assessment , 2013, The AAPS Journal.

[2]  Arunan Kaliyaperumal,et al.  Immunogenicity testing strategy and bioanalytical assays for antibody-drug conjugates. , 2013, Bioanalysis.

[3]  J. Hillert,et al.  Characterization of anti-natalizumab antibodies in multiple sclerosis patients , 2013, Multiple sclerosis.

[4]  Bo Yao,et al.  Conformational B-Cell Epitope Prediction on Antigen Protein Structures: A Review of Current Algorithms and Comparison with Common Binding Site Prediction Methods , 2013, PloS one.

[5]  J. Oldenburg,et al.  Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients. , 2013, Blood.

[6]  X. Mariette,et al.  Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective , 2012, Annals of the rheumatic diseases.

[7]  N. Chirmule,et al.  Measurement of Anti-Erythropoiesis-Stimulating Agent IgG4 Antibody as an Indicator of Antibody-Mediated Pure Red Cell Aplasia , 2012, Clinical and Vaccine Immunology.

[8]  Troy E. Barger,et al.  A detailed examination of the antibody prevalence and characteristics of anti-ESA antibodies. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[9]  A. Matucci,et al.  Skin testing and infliximab-specific antibodies detection as a combined strategy for preventing infusion reaction , 2012, Internal and Emergency Medicine.

[10]  Troy E. Barger,et al.  Development and characterization of a human antibody reference panel against erythropoietin suitable for the standardization of ESA immunogenicity testing. , 2012, Journal of immunological methods.

[11]  S. Tatarewicz,et al.  Epitope characterization of pre-existing and developing antibodies to an aglycosylated monoclonal antibody therapeutic of G1m17,1 allotype. , 2012, Journal of immunological methods.

[12]  Yow-Ming C Wang,et al.  A Survey of Applications of Biological Products for Drug Interference of Immunogenicity Assays , 2012, Pharmaceutical Research.

[13]  M. Nurmohamed,et al.  IgG4 Production Against Adalimumab During Long Term Treatment of RA Patients , 2012, Journal of Clinical Immunology.

[14]  B. Meibohm,et al.  Immunogenicity to Therapeutic Proteins: Impact on PK/PD and Efficacy , 2012, The AAPS Journal.

[15]  U. Kopylov,et al.  The decline of anti‐drug antibody titres after discontinuation of anti‐TNFs: implications for predicting re‐induction outcome in IBD , 2012, Alimentary pharmacology & therapeutics.

[16]  Anne R. Pariser,et al.  The role of immune tolerance induction in restoration of the efficacy of ERT in Pompe disease , 2012, American journal of medical genetics. Part C, Seminars in medical genetics.

[17]  S. Bombardieri,et al.  Hypersensitivity reactions during treatment with infliximab, etanercept, and adalimumab. , 2012, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[18]  C. Yanover,et al.  Pharmacogenetics and the immunogenicity of protein therapeutics , 2011, Nature Biotechnology.

[19]  L. Aarden,et al.  Differential effect of drug interference in immunogenicity assays. , 2011, Journal of immunological methods.

[20]  Yuan-Tsong Chen,et al.  The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: Lessons learned from infantile Pompe disease , 2011, Genetics in Medicine.

[21]  Viswanath Devanarayan,et al.  Recommendations for the validation of cell-based assays used for the detection of neutralizing antibody immune responses elicited against biological therapeutics. , 2011, Journal of pharmaceutical and biomedical analysis.

[22]  B. Dijkmans,et al.  Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. , 2011, JAMA.

[23]  K. Bendtzen,et al.  Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease , 2011, Scandinavian journal of gastroenterology.

[24]  S. Singh,et al.  Impact of product-related factors on immunogenicity of biotherapeutics. , 2011, Journal of pharmaceutical sciences.

[25]  Jianzhu Chen,et al.  Antigen-bearing dendritic cells regulate the diverse pattern of memory CD8 T-cell development in different tissues , 2010, Proceedings of the National Academy of Sciences.

[26]  B. Dijkmans,et al.  The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept , 2010, Annals of the rheumatic diseases.

[27]  B. Hsu,et al.  Population pharmacokinetics of golimumab in patients with ankylosing spondylitis: impact of body weight and immunogenicity. , 2010, International journal of clinical pharmacology and therapeutics.

[28]  A. Matucci,et al.  Anti‐infliximab IgE and non‐IgE antibodies and induction of infusion‐related severe anaphylactic reactions , 2010, Allergy.

[29]  R. Monteiro.  The Role of IgA and IgA Fc Receptors as Anti-Inflammatory Agents , 2010, Journal of Clinical Immunology.

[30]  A. Rosenberg,et al.  Elimination of antibodies to recombinant enzyme in Pompe's disease. , 2009, The New England journal of medicine.

[31]  T. Platts-Mills,et al.  Anaphylaxis syndromes related to a new mammalian cross-reactive carbohydrate determinant. , 2009, The Journal of allergy and clinical immunology.

[32]  I. Pastan,et al.  Removal of B cell epitopes as a practical approach for reducing the immunogenicity of foreign protein-based therapeutics. , 2009, Advanced drug delivery reviews.

[33]  Masanori Onda,et al.  Reducing the immunogenicity of protein therapeutics. , 2009, Current drug targets.

[34]  Viswanath Devanarayan,et al.  Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. , 2008, Journal of pharmaceutical and biomedical analysis.

[35]  Wei Li,et al.  ElliPro: a new structure-based tool for the prediction of antibody epitopes , 2008, BMC Bioinformatics.

[36]  H. Schellekens.  Recombinant human erythropoietins, biosimilars and immunogenicity. , 2008, Journal of nephrology.

[37]  Viswanath Devanarayan,et al.  Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. , 2008, Journal of immunological methods.

[38]  Quynh-Thu Le,et al.  Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. , 2008, The New England journal of medicine.

[39]  K. Bendtzen,et al.  Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. , 2007, Rheumatology.

[40]  Anne S De Groot,et al.  Immunogenicity of protein therapeutics. , 2007, Trends in immunology.

[41]  J. Berlin,et al.  High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  D. Masterman,et al.  Development of a Maturing T-Cell-Mediated Immune Response in Patients with Idiopathic Parkinson’s Disease Receiving r-metHuGDNF Via Continuous Intraputaminal Infusion , 2007, Journal of Clinical Immunology.

[43]  M. Tabrizi,et al.  Preclinical and clinical safety of monoclonal antibodies. , 2007, Drug discovery today.

[44]  M. Khamashta,et al.  Autoimmune Diseases Induced by TNF-Targeted Therapies: Analysis of 233 Cases , 2007, Medicine.

[45]  Arunan Kaliyaperumal,et al.  Comparing ELISA and Surface Plasmon Resonance for Assessing Clinical Immunogenicity of Panitumumab , 2007, The Journal of Immunology.

[46]  Gopi Shankar,et al.  A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs , 2007, Nature Biotechnology.

[47]  Marian Kelley,et al.  Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics. , 2007, Journal of immunological methods.

[48]  K. Zou,et al.  Receiver-Operating Characteristic Analysis for Evaluating Diagnostic Tests and Predictive Models , 2007, Circulation.

[49]  James J. Vincent,et al.  Characterization of the B Cell Epitopes Associated with a Truncated Form of Pseudomonas Exotoxin (PE38) Used to Make Immunotoxins for the Treatment of Cancer Patients1 , 2006, The Journal of Immunology.

[50]  O. Lund,et al.  Prediction of residues in discontinuous B‐cell epitopes using protein 3D structures , 2006, Protein science : a publication of the Protein Society.

[51]  Huub Schellekens,et al.  Immunogenicity of biopharmaceuticals. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[52]  B. Dijkmans,et al.  Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation , 2006, Annals of the rheumatic diseases.

[53]  K. Toellner,et al.  B cell clones that sustain long-term plasmablast growth in T-independent extrafollicular antibody responses. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[54]  C. Hager-Braun,et al.  Determination of protein-derived epitopes by mass spectrometry , 2005, Expert review of proteomics.

[55]  Vibha Jawa,et al.  Immunogenicity testing by electrochemiluminescent detection for antibodies directed against therapeutic human monoclonal antibodies. , 2005, Clinical chemistry.

[56]  Lucila Ohno-Machado,et al.  The use of receiver operating characteristic curves in biomedical informatics , 2005, J. Biomed. Informatics.

[57]  Eugen Koren,et al.  An acid dissociation bridging ELISA for detection of antibodies directed against therapeutic proteins in the presence of antigen. , 2005, Journal of immunological methods.

[58]  L. Kappos,et al.  Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. , 2005 .

[59]  K. Haas,et al.  B-1a and B-1b cells exhibit distinct developmental requirements and have unique functional roles in innate and adaptive immunity to S. pneumoniae. , 2005, Immunity.

[60]  R. Hansen,et al.  Antibody pharmacokinetics and pharmacodynamics. , 2004, Journal of pharmaceutical sciences.

[61]  A. Gottlieb,et al.  Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. , 2004, Journal of the American Academy of Dermatology.

[62]  I. Pastan,et al.  Rapid grouping of monoclonal antibodies based on their topographical epitopes by a label-free competitive immunoassay. , 2004, Journal of immunological methods.

[63]  George Scott,et al.  Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. , 2004, Journal of immunological methods.

[64]  An Carbonez,et al.  Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. , 2003, The New England journal of medicine.

[65]  C. Yang,et al.  Thrombocytopenia caused by the development of antibodies to thrombopoietin. , 2001, Blood.

[66]  Bruce N. Rehlaender,et al.  Antibodies as Carrier Proteins , 1998, Pharmaceutical Research.

[67]  J. Stavnezer.  Immunoglobulin class switching. , 1996, Current opinion in immunology.

[68]  R. Jefferis,et al.  Selective IgG subclass deficiency: quantification and clinical relevance , 1990, Clinical and experimental immunology.

[69]  U. Pennsylvania,et al.  Clinical and Laboratory Standards Institute , 2019, Springer Reference Medizin.

[70]  M. V. Regenmortel,et al.  What is a B-cell epitope? , 2009 .

[71]  J. Uetrecht,et al.  Immune-mediated adverse drug reactions. , 2009, Chemical research in toxicology.

[72]  K. Alugupalli.  A distinct role for B1b lymphocytes in T cell-independent immunity. , 2008, Current topics in microbiology and immunology.

[73]  M. Subramanyam.  Case Study: Immunogenicity of Natalizumab , 2008 .

[74]  J. Tcheng,et al.  Consequences of immunogenicity to the therapeutic monoclonal antibodies ReoPro and Remicade. , 2003, Developments in biologicals.

[75]  L. Herzenberg,et al.  Origin of murine B cell lineages. , 1993, Annual review of immunology.